Article
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.
Blood cancer journal - 11 Jul 2022
Bérard Emilie, Röllig Christoph, Bertoli Sarah, Pigneux Arnaud, Tavitian Suzanne, Kramer Michael, Serve Hubert, Bornhäuser Martin, Platzbecker Uwe, Müller-Tidow Carsten, Baldus Claudia D, Martínez-Cuadrón David, Serrano Josefina, Martínez-Sánchez Pilar, Arbolí Eduardo Rodríguez, Gil Cristina, Bergua Juan, Bernal Teresa, de la Fuente Burguera Adolfo, Delabesse Eric, Bidet Audrey, Dumas Pierre-Yves, Montesinos Pau, Récher Christian
Abstract excerpt
In a context of therapeutic revolution in older adults with AML, it is becoming increasingly important to select patients for the various treatment options by taking account of short-term efficacy and toxicity as well as long-term survival. Here, the data from three European registries for 1,199 AML patients aged 70 years or older treated with intensive chemotherapy were used to develop a prognostic scoring...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.